TerminatedPhase 2NCT04502433

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

Studying Adult acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chiesi Farmaceutici S.p.A.
Principal Investigator
Clark Howard, Prof. /MD
University College, London
Intervention
CUROSURF® (poractant alfa)(drug)
Enrollment
22 enrolled
Eligibility
18-80 years · All sexes
Timeline
20212022

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04502433 on ClinicalTrials.gov

Other trials for Adult acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Adult acute respiratory distress syndrome

← Back to all trials